of alterations are missed by small hotspot panels.1
of patients tested with non-NGS methods had a missed targeted therapy option versus 3% of patients who underwent comprehensive genomic profiling.2
CMP reduces the chance of missing genomic alterations and targeted therapy options.
CMP generates a comprehensive roadmap for therapy selection today, while facilitating the future use of newly approved biomarkers and treatments, plus clinical trial enrollment. CMP simplifies and streamlines clinical decision-making, empowering physicians to develop the most informed care plans for patients. By enabling selection of the right therapy from the start and avoid costly, non-beneficial treatments, CMP can help improve outcomes while minimizing downstream costs, ineffective therapies, and unnecessary toxicity.
*Not available in all locations.
By unleashing the full potential of CMP in cancer care, you can ensure no vital information is left undiscovered in your pursuit of improved patient outcomes.
Place an order today for a comprehensive, personalized Caris profiling report.